283 related articles for article (PubMed ID: 37500970)
1. Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.
Takahari D; Nakayama I
Int J Clin Oncol; 2023 Nov; 28(11):1431-1441. PubMed ID: 37500970
[TBL] [Abstract][Full Text] [Related]
2. Changes in the therapeutic landscape of oesophago-gastric cancers.
Fokter Dovnik N; Smyth EC
Curr Opin Oncol; 2021 Jul; 33(4):362-367. PubMed ID: 33720069
[TBL] [Abstract][Full Text] [Related]
3. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.
Cartwright E; Cunningham D
Curr Treat Options Oncol; 2017 Nov; 18(12):69. PubMed ID: 29143893
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Fritsch R; Hoeppner J
Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):285-291. PubMed ID: 30791774
[TBL] [Abstract][Full Text] [Related]
6. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
Tang JL; Zhang B; Xu JP; Qi L; Xin D; Wang L; Wang BZ; Tian YT; Li Y; Huang J
Cancer Med; 2023 Mar; 12(5):5639-5648. PubMed ID: 36341590
[TBL] [Abstract][Full Text] [Related]
7. Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Möhring C; Mańczak A; Timotheou A; Sadeghlar F; Zhou T; Mahn R; Monin MB; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Sommer N; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Int J Cancer; 2023 Aug; 153(3):609-622. PubMed ID: 36919950
[TBL] [Abstract][Full Text] [Related]
8. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
9. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
10. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Briasoulis E; Fatouros M; Roukos DH
Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
[No Abstract] [Full Text] [Related]
11. [Neoadjuvant and perioperative treatment of gastric cancer, current studies and new biomarkers].
Stocker G; Thieme R; Lordick F
Chirurg; 2021 Jun; 92(6):499-505. PubMed ID: 33566116
[TBL] [Abstract][Full Text] [Related]
12. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
14. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
16. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
17. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
18. FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
Shariff B; Mehta R
Chin Clin Oncol; 2023 Jun; 12(3):24. PubMed ID: 37303220
[TBL] [Abstract][Full Text] [Related]
19. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M;
N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]